Stifel Nicolaus upgraded shares of Aimmune Therapeutics (NASDAQ:AIMT) to a positive rating in a research report released on Monday morning, The Fly reports.
Other research analysts also recently issued reports about the company. Roth Capital started coverage on Aimmune Therapeutics in a research report on Friday, July 12th. They set a buy rating and a $45.00 price objective for the company. Royal Bank of Canada lowered their target price on shares of Aimmune Therapeutics to $50.00 and set an outperform rating for the company in a research note on Friday, August 9th. BidaskClub cut shares of Aimmune Therapeutics from a buy rating to a hold rating in a research note on Saturday, August 24th. Credit Suisse Group began coverage on shares of Aimmune Therapeutics in a research note on Tuesday, May 21st. They issued an outperform rating and a $30.00 target price for the company. Finally, Wedbush set a $79.00 target price on shares of Aimmune Therapeutics and gave the stock a buy rating in a research note on Wednesday, August 21st. One analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Aimmune Therapeutics currently has an average rating of Buy and a consensus target price of $42.13.
Shares of Aimmune Therapeutics stock opened at $22.79 on Monday. The company has a debt-to-equity ratio of 0.24, a current ratio of 5.80 and a quick ratio of 5.80. Aimmune Therapeutics has a 1 year low of $16.95 and a 1 year high of $36.12. The company has a market capitalization of $1.42 billion, a P/E ratio of -6.21 and a beta of -0.09. The business has a 50 day moving average price of $20.57 and a 200 day moving average price of $20.79.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.93) by ($0.08). During the same period in the previous year, the business posted ($0.91) earnings per share. As a group, research analysts expect that Aimmune Therapeutics will post -4 EPS for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in AIMT. Cable Hill Partners LLC grew its stake in Aimmune Therapeutics by 81.7% in the 1st quarter. Cable Hill Partners LLC now owns 1,112 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 500 shares during the period. Manchester Capital Management LLC purchased a new stake in shares of Aimmune Therapeutics during the 1st quarter valued at $27,000. Marshall Wace North America L.P. purchased a new stake in shares of Aimmune Therapeutics during the 1st quarter valued at $32,000. Aperio Group LLC purchased a new stake in shares of Aimmune Therapeutics during the 2nd quarter valued at $76,000. Finally, Bank of Montreal Can grew its stake in shares of Aimmune Therapeutics by 336.3% during the 2nd quarter. Bank of Montreal Can now owns 4,363 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 3,363 shares during the period. 78.06% of the stock is owned by hedge funds and other institutional investors.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Further Reading: How Do Front-End Loads Impact an Investment?
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.